Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer
-
Peters, S. (Lausanne University Hospital)
;
Camidge, David Ross (University of Colorado) ;
Shaw, A. T. (Massachusetts General Hospital (Boston)) ;
Gadgeel, S. (University of Michigan) ;
Ahn, Jin Seop (Samsung Medical Center. Sungkyunkwan University School of Medicine) ;
Kim, Dong-Wan (Seoul National University Hospital) ;
Ou, S. H. I. (School of Medicine) ;
Pérol, M. (Department of Medical Oncology. Léon Bérard Cancer Center) ;
Dziadziuszko, R. (Department of Oncology and Radiotherapy. Medical University of Gdansk) ;
Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zeaiter, A. (F. Hoffmann-La Roche) ;
Mitry, E. (F. Hoffmann-La Roche) ;
Golding, S. (F. Hoffmann-La Roche) ;
Balas, B. (F. Hoffmann-La Roche) ;
Noe, J. (F. Hoffmann-La Roche) ;
Morcos, P. N. (Roche Innovation Center) ;
Mok, T. (State Key Laboratory of South China. Chinese University of Hong Kong)
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
